Roivant Sciences (ROIV) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Roivant Sciences (ROIV) has outperformed Teva Pharmaceutical Industries (TEVA) over the past year, gaining 115.6% versus a gain of 95.2%. Over five years, ROIV leads with a +477.2% price change compared with +304.8% for TEVA. Teva Pharmaceutical Industries is the larger company by market cap ($44.67 billion vs $24.33 billion), about 1.8 times the size.
Teva Pharmaceutical Industries converts more of its revenue into profit, with a net margin of 8.2% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ROIV | TEVA |
|---|---|---|
| Share price | $33.68 | $38.30 |
| Market cap | $24.33B | $44.67B |
| 1-day change | -3.08% | -2.25% |
| YTD return | +60.14% | +25.54% |
| 1-year return | +115.57% | +95.22% |
| 5-year return | +477.24% | +304.75% |
| P/E ratio (TTM) | — | 63.83 |
| Forward P/E | — | 12.39 |
| EPS (TTM) | $-0.53 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.26M | $17.26B |
| Revenue growth (YoY) | -71.57% | +4.32% |
| Net income (latest FY) | $-299.77M | $1.41B |
| Gross margin | — | 51.79% |
| Operating margin | -6235.69% | 12.50% |
| Net margin | -3629.19% | 8.17% |
| 52-week high | $42.50 | $40.79 |
| 52-week low | $15.90 | $18.83 |
| Distance from 52-week high | -20.75% | -6.10% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +42.76% | +18.28% |
| Average volume | 7.02M | 5.29M |
| Shares outstanding | 722.32M | 1.17B |
| Employees | 721 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed TEVA by 20.4 percentage points over the past year.
- Teva Pharmaceutical Industries is more profitable, keeping 8.2 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- Teva Pharmaceutical Industries grew revenue faster in its latest fiscal year (+4.32% vs -71.57%).
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
ROIV vs TEVA FAQ
Which is bigger, Roivant Sciences or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $44.67B compared with $24.33B for Roivant Sciences (ROIV).
Which stock has performed better over the past year, ROIV or TEVA?
ROIV returned +115.57% over the past 12 months, compared with +95.22% for TEVA (price return, excluding dividends). Past performance does not predict future results.
Are Roivant Sciences and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.